Skip to main content

Table 2 Algorithms (principal and alternative) to identify people receiving care for chronic HCV infection from the French National Health Data System

From: French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long

  Principal algorithm Alternative algorithm
Items Definitions Modifications compared with principal algorithm
AT LEAST ONE MAJOR CRITERION DURING THE YEAR AMONG THE FOLLOWING:
  HCV genotyping ≥ 1 reimbursement  
HCV antiviral treatment ≥ 1 reimbursement for pegylated interferon and ribavirin (with at least one common delivery date) or for first or second generation DAAs  
HCV RNA quantitative PCR ≥ 3 reimbursements ≥ 2
Hospitalization with a principal or related diagnosis of chronic hepatitis C ≥ 1 hospitalization with a principal or related diagnosis of chronic hepatitis C in medicine, surgery or obstetric services  
Long-term disease (LTD) registration for chronic hepatitis C (“incident patients”) New LTD registrations for chronic hepatitis C  
OR
BOTH THE INTERMEDIATE CRITERION DURING THE YEAR:
  HCV RNA quantitative PCR 2 reimbursements 1
AND AT LEAST ONE MINOR CRITERION DURING THE YEAR AMONG THE FOLLOWING: ≥ 2
  Liver fibrosis assessment ≥ 1 reimbursement for liver biopsy, fibrosis, liver stiffness measurement or blood biomarkers  
Long-term disease registration for chronic hepatitis C (“prevalent patients”) Patients registered with LTD status, excluding those admitted during the year  
Hospitalization with an associated diagnosis of chronic hepatitis C ≥ 1 hospitalization with an associated diagnosis of chronic hepatitis C in medicine, surgery or obstetric services  
  1. Details of selected codes are provided in Additional file 3